Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.55 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3658685 | 0.93 | S1PR1 (0.61) | S1PR1S1PR5KCNH2CYP3A4CYP2C9 | |
| SCHEMBL3749885 | 0.91 | S1PR1 (0.49) | S1PR1S1PR5KCNH2CYP3A4CYP2C9 | |
| SCHEMBL3752329 | 0.89 | S1PR1 (0.53) | S1PR1S1PR5KCNH2CYP3A4CYP2C9 | |
| SCHEMBL3758679 | 0.88 | S1PR1 (0.61) | S1PR1S1PR5KCNH2CYP3A4CYP2C9 | |
| SCHEMBL2909505 | 0.87 | S1PR1 (0.53) | S1PR1KCNH2 | |
| SCHEMBL3661119 | 0.85 | S1PR1 (0.56) | S1PR1S1PR5CYP2C9S1PR3 | |
| SCHEMBL3753001 | 0.85 | S1PR1 (0.46) | S1PR1S1PR5S1PR3 | |
| SCHEMBL13786427 | 0.84 | S1PR1 (0.49) | S1PR1S1PR5KCNH2CYP3A4CYP2C9 | |
| SCHEMBL2123484 | 0.80 | S1PR1 (0.63) | S1PR1S1PR5KCNH2CYP3A4CYP2C9 | |
| SCHEMBL13786397 | 0.80 | S1PR1 (0.42) | S1PR1S1PR5KCNH2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263620-B2 | Oxadiazole derivatives active on sphingosine-1-phosphate (SIP) | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-8263620-B2 | Oxadiazole derivatives active on sphingosine-1-phosphate (SIP) | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-8263620-B2 | Oxadiazole derivatives active on sphingosine-1-phosphate (SIP) | GLAXO GROUP LIMITED (GB) | 2012-09-11 | — | — | US | disclosed |
| US-20100298373-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298373-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298373-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| WO-2009080728-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298373-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885S1PR5 6/4885KCNH2 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.